SynthesisBMJ (Clinical research ed.)2025
P2Y
Synthesis in BMJ (Clinical research ed.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clopidogrel versus aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: an updated meta-analysis of 162,829 patients.European journal of clinical pharmacology · 2026Pooled it
- Knowledge domain and evolutionary trends of P2Y receptors in cardiovascular diseases: a bibliometric and altmetric analysis.Frontiers in pharmacology · 2025Pooled it
- Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year.Reviews in cardiovascular medicine · 2026Review
- Antithrombotic Therapy in Primary and Secondary Prevention of Coronary Artery Disease.Journal of clinical medicine · 2026Review
- Time- and risk-dependent effects of dual antiplatelet therapy targeting the P2Y12 receptor after CABG: A network meta-analysis of graft permeability and clinical outcomes.Journal of thrombosis and thrombolysis · 2026Review
- Is Aspirin Still Indispensable After PCI-Rethinking Dual Antiplatelet Therapy in Contemporary Practice.Journal of cardiovascular development and disease · 2026Review
- Optimal Medical Therapy Targeting Metabolic Status for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2026Review
- Comparison of P2YArchives of medical sciences. Atherosclerotic diseases · 2026Review
- Efficacy and Safety of Clopidogrel Versus Aspirin Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.Clinical Medicine Insights. Cardiology · 2026Article
- Article
- Managing patients with a history of arterial disease and new venous thromboembolism.Hematology. American Society of Hematology. Education Program · 2025Article
- Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2025Review
- Intravascular Imaging Guidance for Percutaneous Coronary Interventions.Journal of clinical medicine · 2025Review
- P2YReviews in cardiovascular medicine · 2025Article
- Antiplatelet Monotherapies for Long-Term Secondary Prevention Following Percutaneous Coronary Intervention.Journal of clinical medicine · 2025Review
- Platelet Hyperactivation Plays a Critical Role in Exacerbating Skin Lesions in Rats with Psoriasis and Blood Stasis Syndrome.Journal of inflammation research · 2025Article
- P2Y12 Inhibitor or Aspirin Monotherapy for Chronic Coronary Disease: A Nationwide Cohort Study.Cardiovascular therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the long term comparative effectiveness of P2Y
designIndividual participant data (IPD) meta-analysis of randomised clinical trials. DATA SOURCES: PubMed/Medline, Scopus, Web of Science, and Ovid/Embase. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised trials investigating monotherapy with a P2Y DATA EXTRACTION AND SYNTHESIS: Anonymised IPD were extracted and transferred to the coordinating centre by dedicated electronic spreadsheets. Data were primarily combined by mixed effects models (one stage analysis) and complemented with multivariable mixed effects models and two stage analyses based on random effects models. The primary and co-primary outcomes were a composite of major adverse cardiac and cerebrovascular events (MACCE) and major bleeding, respectively. The secondary outcomes included a net composite of adverse cardiac and cerebrovascular events (NACCE), derived from the combination of the primary and co-primary outcomes, and individual ischaemic and bleeding events.
resultsA total of 16 117 patients assigned to P2Y
conclusionsIn patients who had undergone PCI and discontinued DAPT, at a follow-up of about 5.5 years, P2Y REVIEW REGISTRATION: PROSPERO CRD42024517983.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.